| Syed Asim Razvi, MD | |
|
1 Elliot Way, Suite 200, Manchester, NH 03103-3502 | |
| (603) 663-2315 | |
| (603) 647-9180 |
| Full Name | Syed Asim Razvi |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 30 Years |
| Location | 1 Elliot Way, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659335081 | NPI | - | NPPES |
| 3087990 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 10569 (New Hampshire) | Secondary |
| 207L00000X | Anesthesiology | 10569 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Amoskeag Anesthesia Pllc | 1759375983 | 93 |
| New Hampshire Neurospine Institute Pa | 4486634235 | 24 |
| Four Seasons Orthopaedic Center Pllc | 5193791804 | 41 |
| Elliot Professional Services | 6103727920 | 304 |
News Archive
Researchers at Duke University Medical Center have identified a possible biomarker for measuring progress in breast cancer chemoprevention trials, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.
In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
› Verified 5 days ago
| Entity Name | Elliot Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285627935 PECOS PAC ID: 6103727920 Enrollment ID: O20040115000634 |
News Archive
Researchers at Duke University Medical Center have identified a possible biomarker for measuring progress in breast cancer chemoprevention trials, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.
In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
› Verified 5 days ago
| Entity Name | Amoskeag Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104883511 PECOS PAC ID: 1759375983 Enrollment ID: O20040513001385 |
News Archive
Researchers at Duke University Medical Center have identified a possible biomarker for measuring progress in breast cancer chemoprevention trials, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.
In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
› Verified 5 days ago
| Entity Name | New Hampshire Neurospine Institute Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073627329 PECOS PAC ID: 4486634235 Enrollment ID: O20040722000303 |
News Archive
Researchers at Duke University Medical Center have identified a possible biomarker for measuring progress in breast cancer chemoprevention trials, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.
In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
› Verified 5 days ago
| Entity Name | Four Seasons Orthopaedic Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881772242 PECOS PAC ID: 5193791804 Enrollment ID: O20040903000533 |
News Archive
Researchers at Duke University Medical Center have identified a possible biomarker for measuring progress in breast cancer chemoprevention trials, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.
In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Syed Asim Razvi, MD 1 Elliot Way, Suite 200, Manchester, NH 03103-3502 Ph: (603) 663-2315 | Syed Asim Razvi, MD 1 Elliot Way, Suite 200, Manchester, NH 03103-3502 Ph: (603) 663-2315 |
News Archive
Researchers at Duke University Medical Center have identified a possible biomarker for measuring progress in breast cancer chemoprevention trials, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Nuvo Research Inc. a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary endpoint.
In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
› Verified 5 days ago
Rebecca Elizabeth Kadish, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Sean E Hunt, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Dr. Charles Beck Eastwood, M.D., C.M. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Elliot Way, Suite 200, Manchester, NH 03103 Phone: 603-663-2315 | |
Alan Mekler, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1 Elliot Way, Suite 200, Manchester, NH 03103 Phone: 603-663-2315 Fax: 603-647-9180 | |
Corinne E Cambio, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-650-5922 | |
Dennis L Kelly, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 88 Mcgregor St, Ste 303, Manchester, NH 03102 Phone: 603-647-9325 Fax: 603-647-2453 | |
Martin Leonard Ginsberg, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1 Elliot Way, Suite 200, Manchester, NH 03103 Phone: 603-663-2315 Fax: 603-647-9180 |